Myriad Genetics, Inc.

University of Utah Research Foundation

Abbvie Inc.

Ihc Health Services

Victor Abkevich

Alexander Gutin

Kirsten Timms

Donna Shattuck

Deanna L Russell

Jerry Lanchbury

Chris Neff

Julia Reid

Steven Stone

Steven Hunt

Susanne Wagner

Nicola Jane Camp

Jeremy C Packer

Alfred Guirguis

Esther Elishaev

Anahita Bhathena

Lisa Cannon-Albright

Christopher Neff

Srikanth Jammulapati

David A Katz

Julie A DeLoia

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Methods and materials for assessing homologous recombination deficiency

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Method of treating cancer

Method for treating cancer

Methods and materials for assessing loss of heterozygosity

The present invention relates to DEP2, as well as other proteins, and their uses in connection with the treatment of major depression or related disorders.

Dep2 and its uses in major depressive disorder and other related disorders

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human obesity and diabetes predisposing gene, specifically the TBC1D1 gene, some mutant alleles of which cause susceptibility to obesity and/or diabetes. More specifically, the invention relates to germline mutations in the TBC1D1 gene and their use in the diagnosis of predisposition to obesity and diabetes. Finally, the invention relates to the screening of the TBC1D1 gene for mutations/alterations, which are useful for diagnosing the predisposition to obesity.

Obesity gene and use thereof

The invention relates to copy number profile analysis. Specifically, copy number profile analysis is used to determine whether two or more separate tumors in a single individual are derived from a common source.

Gene copy number profiling

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human depression predisposing gene, specifically the apoptotic protease activating factor 1 (APAF1) gene, some mutant alleles of which cause susceptibility to depression. More specifically, the invention relates to germline mutations in the APAF1 gene and their use in the diagnosis of predisposition to depression. The invention also relates to the prophylaxis and/or therapy of depression associated with a mutation in the APAF1 gene. The invention further relates to the screening of drugs for depression therapy. Finally, the invention relates to the screening of the APAF1 gene for mutations/alterations, which are useful for diagnosing the predisposition to depression.

Depression gene

Growing community of inventors

Salt Lake City, UT, United States of America

Victor Abkevich